| 3.1503 0 (0.01%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.8  |
1-year : | 4.44 |
| Resists | First : | 3.25 |
Second : | 3.8 |
| Pivot price | 3 |
|||
| Supports | First : | 2.58 |
Second : | 2.16 |
| MAs | MA(5) : | 3.12 |
MA(20) : | 2.94 |
| MA(100) : | 2.65  |
MA(250) : | 2.65 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 80.7 |
D(3) : | 80.7 |
| RSI | RSI(14): 66 |
|||
| 52-week | High : | 4.4 | Low : | 1.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OPT ] has closed below upper band by 13.4%. Bollinger Bands are 45.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.26 - 3.28 | 3.28 - 3.29 |
| Low: | 3.09 - 3.1 | 3.1 - 3.12 |
| Close: | 3.13 - 3.15 | 3.15 - 3.17 |
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Tue, 10 Sep 2024
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight - StockTitan
Tue, 10 Sep 2024
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
Sun, 08 Sep 2024
Opthea Limited Eyes Breakthrough in Vision Treatment - TipRanks
Thu, 05 Sep 2024
Opthea Announces Executive Leadership Changes and Senior Hires - StockTitan
Thu, 05 Sep 2024
HC Wainwright Weighs in on Opthea Limited's FY2029 Earnings (NASDAQ:OPT) - MarketBeat
Tue, 03 Sep 2024
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 154 (M) |
| Held by Insiders | 8.2238e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9182e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -164 % |
| Return on Assets (ttm) | 535.5 % |
| Return on Equity (ttm) | -83.5 % |
| Qtrly Rev. Growth | 261860 % |
| Gross Profit (p.s.) | -42.43 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -161 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -72.46 |
| Dividend | 0 |
| Forward Dividend | 71430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|